Brind.

Canada's PMPRB Tables 2025 Report on Patented Medicine Prices

3 reports, 1 independent Updated Sat 03:30
No new developments lately Reached 3 outlets in its first 24 hours
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The Patented Medicine Prices Review Board tabled its 2025 Annual Report, which reviews trends in the prices and sales of patented medicines in Canada. The report noted that sales of patented medicines reached $24.4 billion in 2025, representing 48% of all medicine sales in Canada. In 2025, 1,086 patented medicines for human use were reported to the board.

From brantfordexpositor.ca

Why it matters

Some supportBrind's analysis of the reports

The PMPRB reviews patented medicine prices to protect Canadians from excessive pricing related to patents. The report highlighted that Canadian list prices were the third highest among the PMPRB11 countries and ranked seventh highest among 35 Organization for Economic Co-operation and Development countries.

From brantfordexpositor.ca

Who's involved

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story